This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

c.US$2m multiplex diagnostic test contract win

Development, scale-up and technical transfer for a semi-quantitative, multiplex lateral flow test system

York, U.K.  10 November 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, announces a new contract win with an expected value of approximately US$2 million.

The Company has signed a Master Service Agreement ("MSA") with a US-based company for the development and scale up to manufacture of a semi-quantitative, multiplex lateral flow test system. The MSA covers the feasibility, optimisation, scale-up, and technical transfer to manufacturing of the test for multiple analytes. The project is expected to take approximately 24 months via works orders under the MSA which are expected to total c. US$2 million. The project will be run from the Company's Madison, Wisconsin facilities.

This contract win is another example of the strength of Abingdon Health's CDMO offering which provides customers with comprehensive support to take an idea through to commercial success. The expansion of the Company's Madison, Wisconsin, USA manufacturing capabilities, which is being accelerated following the recent £3.2m (net) fundraise and placing, satisfies the increasing demand from USA-based customers requiring development and manufacture. The Company is well placed to do this and has the benefit of being supported by the Group's full CDMO and regulatory services offering from York, UK.

Abingdon Health's brochure outlines the comprehensive support the Group provides to its international and UK customers.

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented: "This contract award demonstrates the value of our comprehensive CDMO platform, and the benefit of our dual sites in USA and UK. It also illustrates the power and flexibility of lateral flow testing. The ability to measure multiple analytes semi-quantitatively, in a single test system, illustrates the utility of lateral flow testing beyond the more widely known single parameter qualitative 'yes/no' devices. 

"The expertise and experience of Abingdon scientists and the full end-to-end CDMO service offering continues to resonate well with current and potential clients."

Enquiries:

​

About Abingdon Health

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.   

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success. 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK.  Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities. 

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.